title: Effect of the alpha 2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey.
abstract: 1. The motor effect of the alpha 2 adrenoreceptor antagonist, idazoxan, was compared to that of L-dopa in MPTP-treated monkeys. 2. Idazoxan 2.0 mg/kg improved parkinsonian motor abnormalities which was comparable to the effects of a minimal effective dose of L-dopa. 3. At 2.0 and 5.0 mg/kg, the parkinsonian rigidity was the item most frequently alleviated by idazoxan (respectively 63.6% and 68.2%). 4. These findings provide support for the therapeutic utility of alpha 2 antagonists in the treatment of Parkinson's disease.
authors.affiliation: Laboratoire de Neurophysiologie, CNRS UMR 5543, Université de Bordeaux II, France.
authors.forename: E
authors.initials: E
authors.lastname: Bezard
authors.forename: C
authors.initials: C
authors.lastname: Brefel
authors.forename: F
authors.initials: F
authors.lastname: Tison
authors.forename: H
authors.initials: H
authors.lastname: Peyro-Saint-Paul
authors.forename: P
authors.initials: P
authors.lastname: Ladure
authors.forename: O
authors.initials: O
authors.lastname: Rascol
authors.forename: C E
authors.initials: CE
authors.lastname: Gross
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000494:pharmacology*; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000818:Animals; D004195:Disease Models, Animal; D015259:Dopamine Agents / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D005260:Female; D019329:Idazoxan / Q000494:pharmacology*; D008252:Macaca fascicularis; D019957:Motor Skills Disorders / Q000139:chemically induced* / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy
chemical_list: D000317:Adrenergic alpha-Antagonists; D015259:Dopamine Agents; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D019329:Idazoxan